CJC-1295 for growth hormone support

What the evidence says

Evidence tier: Strong clinical. Multiple human studies support the dosing protocol; not yet FDA-labeled for this exact indication but close.

• CJC-1295 is a long-acting GHRH (growth-hormone-releasing hormone) analog - it tells your pituitary gland to make more of its own growth hormone.
• Phase 1 and 2 trials (Teichman et al., 2006) showed sustained 2-10x increases in growth hormone over a week.
• Most-prescribed peptide pair in US compounding for body composition - usually stacked with Ipamorelin.

Protocol notes

100mcg subcutaneous before bed, 5 days per week. Most often stacked with Ipamorelin in the same shot.

Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.

What to skip

• Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
• Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
• Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.

Where to go next

• Full CJC-1295 directory entry - status, sourcing, studies, what to skip
• What are peptides - if you skipped the foundation
• How peptides actually work - mechanism in plain English
• The Tier List - which ones to take seriously
• Subscribe to the dispatch

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.

-> Subscribe free